Clinical Trial Update: Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) [Phase 3]

View source ↗

Summary

Phase 3 TOPS trial comparing 400 mg versus 800 mg imatinib in chronic-phase chronic myeloid leukemia was terminated; results were posted in February 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia, Myeloid, Chronic Phase | Phase 3 | Status: TERMINATED | Results posted: 2012-02-03